June 13, 2011 / 12:38 AM / 8 years ago

Hanwha wins $720 mln biosimilar license deal with Merck

SEOUL, June 13 (Reuters) - South Korea’s Hanwha Chemical said on Monday it had won a license deal worth $720 million for its biosimilar product with Merck Sharp & Dohme Research Ltd, a subsidiary of U.S. drug firm Merck & Co .

The contract will cover global sales of the licensed product excluding South Korea and Turkey and will last until the end of 2024, Hanwha said in a statement. (Reporting by Miyoung Kim; Editing by Ken Wills)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below